FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Vladimir Tolmachev

Research Profile

Chemicals & Drugs

Anatomy

Tumor Cell Line

Living Beings

Concepts & Ideas

Tissue Distribution

Procedures

Disorders

Co-author Network

Publications

TOP 3
Hadis Honarvar; Karl Andersson; Nima Jokilaakso; Amelie Eriksson Karlström; Jennie Malmberg; Anna Orlova; Daniel Rosik; Vladimir Tolmachev; Peter Järver
Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging.
Anna Orlova; Mattias Sandstrom; Joanna Strand; Vladimir Tolmachev; Zohreh Varasteh; Karl Andersson; Camilla Hofström; Torbjörn Gräslund
[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours.
Magdalena Malm; Anna Orlova; Stefan Ståhl; Vladimir Tolmachev; Zohreh Varasteh; Tarek Bass; Fredrik Y Frejd; Lindvi Gudmundsdotter; Ingmarie Höidén Guthenberg; Nina Kronqvist; Hanna Lindberg; John Löfblom
Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Vladimir Tolmachev (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Hadis Honarvar; Karl Andersson; Nima Jokilaakso; Amelie Eriksson Karlström; Jennie Malmberg; Anna Orlova; Daniel Rosik; Vladimir Tolmachev; Peter Järver
Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging.
Nuclear medicine and biology 2013;40(3):378-86.
2013: Anna Orlova; Mattias Sandstrom; Joanna Strand; Vladimir Tolmachev; Zohreh Varasteh; Karl Andersson; Camilla Hofström; Torbjörn Gräslund
[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours.
European journal of nuclear medicine and molecular imaging 2013;40(3):439-49.
2013: Magdalena Malm; Anna Orlova; Stefan Ståhl; Vladimir Tolmachev; Zohreh Varasteh; Tarek Bass; Fredrik Y Frejd; Lindvi Gudmundsdotter; Ingmarie Höidén Guthenberg; Nina Kronqvist; Hanna Lindberg; John Löfblom
Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification.
PloS one 2013;8(5):e62791.
2012: Seyed Jalal Hosseinimehr; Vladimir Tolmachev; Anna Orlova
Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design.
Drug discovery today 2012;17(21-22):1224-32.
2012: Anna Perols; Ramkumar Selvaraju; Joanna Strand; Hadis Honarvar; Anna Orlova; Amelie Eriksson Karlström; Vladimir Tolmachev
Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
Bioconjugate chemistry 2012;23(8):1661-70.
2012: Vladimir Tolmachev; Thuy A Tran; Lars Abrahmsén; Daniel Rosik; Anna Sjöberg; Anna Orlova
Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2012;53(6):953-60.
2012: Hanna Lindberg; Anna Orlova; Stefan Ståhl; Mohamed Altai; Torbjörn Gräslund; Camilla Hofström; Hadis Honorvar; Helena Wållberg; Vladimir Tolmachev
Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2012;33(3):641-51.
2012: Mohamed Altai; Frederic Boschetti; Amelie Eriksson Karlström; Anna Orlova; Anna Perols; Mattias Sandström; Vladimir Tolmachev
Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA.
Nuclear medicine and biology 2012;39(4):518-29.
2012: Mohamed Altai; Seyed Jalal Hosseinimehr; Anna Orlova; Maria Rosestedt; Vladimir Tolmachev; Helena Wållberg; Stefan Ståhl
Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules.
Amino acids 2012;42(5):1975-85.
2012: Daniel Rosik; Mattias Sandström; Zohreh Varasteh; Mohamed Altai; Amelie Eriksson Karlström; Jennie Malmberg; Anna Orlova; Vladimir Tolmachev
Direct comparison of 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging.
European journal of nuclear medicine and molecular imaging 2012;39(4):693-702.
2012: Jennie Malmberg; Anna Orlova; Anna Perols; Mattias Sandström; Vladimir Tolmachev; Zohreh Varasteh; Mohamed Altai; Alexis Braun; Ulrike Garske; Amelie Eriksson Karlström
Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.
European journal of nuclear medicine and molecular imaging 2012;39(3):481-92.
2012: Joachim Feldwisch; Vladimir Tolmachev
Engineering of affibody molecules for therapy and diagnostics.
Methods in molecular biology (Clifton, N.J.) 2012;899():103-26.
2011: Jennie Malmberg; Mattias Sandström; Vladimir Tolmachev; Kenneth Wester; Anna Orlova
Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.
Nuclear medicine and biology 2011;38(8):1093-102.
2011: Karl Sandström; Diana Spiegelberg; Vladimir Tolmachev; Irina Velikyan; Anna-Karin Haylock; Heewa Kareem; Hans Lundqvist; Marika Nestor
Improved tumor-to-organ ratios of a novel 67Ga-human epidermal growth factor radionuclide conjugate with preadministered antiepidermal growth factor receptor affibody molecules.
Cancer biotherapy & radiopharmaceuticals 2011;26(5):593-601.
2011: Seyed Jalal Hosseinimehr; Vladimir Tolmachev; Bo Stenerlöw
125I-labeled quercetin as a novel DNA-targeted radiotracer.
Cancer biotherapy & radiopharmaceuticals 2011;26(4):469-75.
2011: Vladimir Tolmachev; Mattias Sandström; Barbro Baastrup; Joachim Feldwisch; Malin Lindborg; Anna Orlova
Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate.
Nuclear medicine and biology 2011;38(5):697-706.
2011: Camilla Hofstrom; Anna Orlova; Mohamed Altai; Torbjorn Graslund; Fredrik Wangsell; Vladimir Tolmachev
Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with (99m)Tc, (111)In, and (125)I.
Journal of medicinal chemistry 2011;54(11):3817-26.
2011: Vladimir Tolmachev; Anna Perols; Mattias Sandström; Mohamed Altai; Frederic Boschetti; Amelie Eriksson Karlström; Anna Orlova
Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules.
Bioconjugate chemistry 2011;22(5):894-902.
2011: Jennie Malmberg; Vladimir Tolmachev; Anna Orlova
Imaging agents for in vivo molecular profiling of disseminated prostate cancer--targeting EGFR receptors in prostate cancer: comparison of cellular processing of [111In]-labeled affibody molecule Z(EGFR:2377) and cetuximab.
International journal of oncology 2011;38(4):1137-43.
2011: Helena Wållberg; Anna Orlova; Mohammed Altai; Seyed Jalal Hosseinimehr; Charles Widström; Jennie Malmberg; Stefan Ståhl; Vladimir Tolmachev
Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011;52(3):461-9.
2011: Vladimir Tolmachev; Helena Wållberg; Mattias Sandström; Monika Hansson; Anders Wennborg; Anna Orlova
Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels.
European journal of nuclear medicine and molecular imaging 2011;38(3):531-9.
2011: Helena Wållberg; Per-Ke Löfdahl; Kirsten Tschapalda; Mathias Uhlén; Vladimir Tolmachev; Per-Ke Nygren; Stefan Ståhl
Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand.
Protein expression and purification 2011;76(1):127-35.
2011: Jan Terje Andersen; Rikard Pehrson; Vladimir Tolmachev; Muluneh Bekele Daba; Lars Abrahmsén; Caroline Ekblad
Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain.
The Journal of biological chemistry 2011;286(7):5234-41.
2011: Marika Nestor; Magnus Sundström; Matti Anniko; Vladimir Tolmachev
Effect of cetuximab in combination with alpha-radioimmunotherapy in cultured squamous cell carcinomas.
Nuclear medicine and biology 2011;38(1):103-12.
2010: Vladimir Tolmachev; Camilla Hofström; Jennie Malmberg; Sara Ahlgren; Seyed Jalal Hosseinimehr; Mattias Sandström; Lars Abrahmsén; Anna Orlova; Torbjörn Gräslund
HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [⁹⁹(m)Tc(CO)₃](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation.
Bioconjugate chemistry 2010;21(11):2013-22.
2010: Vladimir Tolmachev; Sharon Stone-Elander; Anna Orlova
Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls.
The lancet oncology 2010;11(10):992-1000.
2010: Sara Ahlgren; Vladimir Tolmachev
Radionuclide molecular imaging using Affibody molecules.
Current pharmaceutical biotechnology 2010;11(6):581-9.
2010: Sara Ahlgren; Kristofer Andersson; Vladimir Tolmachev
Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine.
Nuclear medicine and biology 2010;37(5):539-46.
2010: Sara Ahlgren; Anna Orlova; Helena Wållberg; Monika Hansson; Mattias Sandström; Richard Lewsley; Anders Wennborg; Lars Abrahmsén; Vladimir Tolmachev; Joachim Feldwisch
Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2010;51(7):1131-8.
2010: Vladimir Tolmachev; Irina Velikyan; Mattias Sandström; Anna Orlova
A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue.
European journal of nuclear medicine and molecular imaging 2010;37(7):1356-67.
2010: John Löfblom; Joachim Feldwisch; Vladimir Tolmachev; J Carlsson; Stefan Ståhl; F Y Frejd
Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications.
FEBS letters 2010;584(12):2670-80.
2010: Richard P Baum; Vikas Prasad; Dirk Müller; Christiane Schuchardt; Anna Orlova; Anders Wennborg; Vladimir Tolmachev; Joachim Feldwisch
Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2010;51(6):892-7.
2010: Vladimir Tolmachev; Sharon Stone-Elander
Radiolabelled proteins for positron emission tomography: Pros and cons of labelling methods.
Biochimica et biophysica acta 2010;1800(5):487-510.
2010: Vladimir Tolmachev; Daniel Rosik; Helena Wållberg; Anna Sjöberg; Mattias Sandström; Monika Hansson; Anders Wennborg; Anna Orlova
Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount.
European journal of nuclear medicine and molecular imaging 2010;37(3):613-22.
2010: Anna Orlova; Thuy A Tran; Torun Ekblad; Amelie Eriksson Karlström; Vladimir Tolmachev
(186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours.
European journal of nuclear medicine and molecular imaging 2010;37(2):260-9.
2010: Junping Cheng; Mats Engstrom; Tomas Ekberg; Marika Nestor; Matti Anniko; Vladimir Tolmachev
The use of closo-dodecaborate-containing linker improves targeting of HNSCC xenografts with radioiodinated chimeric monoclonal antibody U36.
Molecular medicine reports 2010;3(1):155-60.
2010: Seyed Jalal Hosseinimehr; Anna Orlova; Vladimir Tolmachev
Preparation and in vitro evaluation of 111In-CHX-A"-DTPA-labeled anti-VEGF monoclonal antibody bevacizumab.
Human antibodies 2010;19(4):107-11.
2010: Vladimir Tolmachev; Anna Orlova
Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets.
Current medicinal chemistry 2010;17(24):2636-55.
2009: Thuy A Tran; Daniel Rosik; Lars Abrahmsén; Mattias Sandström; Anna Sjöberg; Helena Wållberg; Sara Ahlgren; Anna Orlova; Vladimir Tolmachev
Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging.
European journal of nuclear medicine and molecular imaging 2009;36(11):1864-73.
2009: Vladimir Tolmachev; Helena Wållberg; Karl Andersson; Anders Wennborg; Hans Lundqvist; Anna Orlova
The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.
European journal of nuclear medicine and molecular imaging 2009;36(9):1460-8.
2009: Torun Ekblad; Anna Orlova; Joachim Feldwisch; Anders Wennborg; Amelie Eriksson Karlström; Vladimir Tolmachev
Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules.
Bioorganic & medicinal chemistry letters 2009;19(14):3912-4.
2009: Sara Ahlgren; Helena Wållberg; Thuy A Tran; Charles Widström; Magnus Hjertman; Lars Abrahmsén; Dietmar Berndorff; Ludger M Dinkelborg; John E Cyr; Joachim Feldwisch; Anna Orlova; Vladimir Tolmachev
Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2009;50(5):781-9.
2009: Vladimir Tolmachev; Eskender Mume; Stefan Sjöberg; Fredrik Y Frejd; Anna Orlova
Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules.
European journal of nuclear medicine and molecular imaging 2009;36(4):692-701.
2009: Anna Orlova; Helena Wållberg; Sharon Stone-Elander; Vladimir Tolmachev
On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2009;50(3):417-25.
2009: Vladimir Tolmachev; Mikaela Friedman; Mattias Sandström; Tove L J Eriksson; Daniel Rosik; Monika Hodik; Stefan Ståhl; Fredrik Y Frejd; Anna Orlova
Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2009;50(2):274-83.
2009: Torun Ekblad; Vladimir Tolmachev; Anna Orlova; Christofer Lendel; Lars Abrahmsén; Amelie Eriksson Karlström
Synthesis and chemoselective intramolecular crosslinking of a HER2-binding affibody.
Biopolymers 2009;92(2):116-23.
2008: Thuy A Tran; Torun Ekblad; Anna Orlova; Mattias Sandström; Joachim Feldwisch; Anders Wennborg; Lars Abrahmsén; Vladimir Tolmachev; Amelie Eriksson Karlström
Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules.
Bioconjugate chemistry 2008;19(12):2568-76.
2008: Vladimir Tolmachev; Heng Xu; Helena Wållberg; Sara Ahlgren; Magnus Hjertman; Anna Sjöberg; Mattias Sandström; Lars Abrahmsén; Martin W Brechbiel; Anna Orlova
Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules.
Bioconjugate chemistry 2008;19(8):1579-87.
2008: Ann-Charlott Steffen; Lovisa Göstring; Vladimir Tolmachev; Stig Palm; Bo Stenerlöw; Jörgen Carlsson
Differences in radiosensitivity between three HER2 overexpressing cell lines.
European journal of nuclear medicine and molecular imaging 2008;35(6):1179-91.
2008: E Nordberg; Anna Orlova; M Friedman; Vladimir Tolmachev; S Ståhl; F Y Nilsson; B Glimelius; Jörgen Carlsson
In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells.
Oncology reports 2008;19(4):853-7.
2008: Mikaela Friedman; Anna Orlova; Eva Johansson; Tove L J Eriksson; Ingmarie Höidén Guthenberg; Vladimir Tolmachev; Fredrik Y Nilsson; Stefan Ståhl
Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule.
Journal of molecular biology 2008;376(5):1388-402.
2008: Vladimir Tolmachev
Imaging of HER-2 overexpression in tumors for guiding therapy.
Current pharmaceutical design 2008;14(28):2999-3019.
2008: Sara Ahlgren; Anna Orlova; Daniel Rosik; Mattias Sandström; Anna Sjöberg; Barbro Baastrup; Olof Widmark; Gunilla Fant; Joachim Feldwisch; Vladimir Tolmachev
Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules.
Bioconjugate chemistry 2008;19(1):235-43.
2007: A Orlova; Daniel Rosik; M Sandström; H Lundqvist; L Einarsson; Vladimir Tolmachev
Evaluation of [(111/114m)In]CHX-A''-DTPA-ZHER2:342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2007;51(4):314-23.
2007: Thuy Tran; Torun Engfeldt; Anna Orlova; Mattias Sandström; Joachim Feldwisch; Lars Abrahmsén; Anders Wennborg; Vladimir Tolmachev; Amelie Eriksson Karlström
(99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
Bioconjugate chemistry 2007;18(6):1956-64.
2007: Torun Engfeldt; Thuy Tran; Anna Orlova; Charles Widström; Joachim Feldwisch; Lars Abrahmsen; Anders Wennborg; Amelie Eriksson Karlström; Vladimir Tolmachev
99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule.
European journal of nuclear medicine and molecular imaging 2007;34(11):1843-53.
2007: Mikael Persson; Igor Sivaev; Karl Johan Winberg; Lars Gedda; Per-Uno Malmstrom; Vladimir Tolmachev
In vitro evaluation of two polyhedral boron anion derivatives as linkers for attachment of radioiodine to the anti-HER2 monoclonal antibody trastuzumab.
Cancer biotherapy & radiopharmaceuticals 2007;22(5):585-96.
2007: Anna Orlova; Joachim Feldwisch; Lars Abrahmsén; Vladimir Tolmachev
Update: affibody molecules for molecular imaging and therapy for cancer.
Cancer biotherapy & radiopharmaceuticals 2007;22(5):573-84.
2007: Anna Orlova; Thuy Tran; Charles Widström; Torun Engfeldt; Amelie Eriksson Karlström; Vladimir Tolmachev
Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors.
International journal of molecular medicine 2007;20(3):397-404.
2007: Ylva Almqvist; Ann-Charlott Steffen; Hans Lundqvist; Holger Jensen; Vladimir Tolmachev; Anders Sundin
Biodistribution of 211At-labeled humanized monoclonal antibody A33.
Cancer biotherapy & radiopharmaceuticals 2007;22(4):480-7.
2007: Junping Cheng; Tomas Ekberg; Mats Engström; Marika Nestor; Holger J Jensen; Vladimir Tolmachev; Matti Anniko
Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma.
The Laryngoscope 2007;117(6):1013-8.
2007: Ann-Charlott Steffen; Ylva Almqvist; Ming-Kuan Chyan; Hans Lundqvist; Vladimir Tolmachev; D Scott Wilbur; Jörgen Carlsson
Biodistribution of 211At labeled HER-2 binding affibody molecules in mice.
Oncology reports 2007;17(5):1141-7.
2007: Torun Engfeldt; Anna Orlova; Thuy Tran; Alexander Bruskin; Charles Widström; Amelie Eriksson Karlström; Vladimir Tolmachev
Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.
European journal of nuclear medicine and molecular imaging 2007;34(5):722-33.
2007: Vladimir Tolmachev; Anna Orlova; Fredrik Y Nilsson; Joachim Feldwisch; Anders Wennborg; Lars Abrahmsén
Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy.
Expert opinion on biological therapy 2007;7(4):555-68.
2007: Vladimir Tolmachev; Anna Orlova; Rikard Pehrson; Joakim Galli; Barbro Baastrup; Karl Andersson; Mattias Sandström; Daniel Rosik; Jörgen Carlsson; Hans Lundqvist; Anders Wennborg; Fredrik Y Nilsson
Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
Cancer research 2007;67(6):2773-82.
2007: Fredrik Y Nilsson; Vladimir Tolmachev
Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy.
Current opinion in drug discovery & development 2007;10(2):167-75.
2007: Anna Orlova; Vladimir Tolmachev; Rikard Pehrson; Malin Lindborg; Thuy Tran; Mattias Sandström; Fredrik Y Nilsson; Anders Wennborg; Lars Abrahmsén; Joachim Feldwisch
Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors.
Cancer research 2007;67(5):2178-86.
2007: Thuy Tran; Torun Engfeldt; Anna Orlova; Charles Widström; Alexander Bruskin; Vladimir Tolmachev; Amelie Eriksson Karlström
In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules.
Bioconjugate chemistry 2007;18(2):549-58.
2007: Thuy Tran; Anna Orlova; Igor Sivaev; Mattias Sandström; Vladimir Tolmachev
Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand.
International journal of molecular medicine 2007;19(3):485-93.
2007: Marc-André Fortin; Anna Orlova; Per-Uno Malmstrom; Vladimir Tolmachev
Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma.
International journal of molecular medicine 2007;19(2):285-91.
2007: Marika Nestor; Tomas Ekberg; John Dring; Guus A M S van Dongen; Kenneth Wester; Vladimir Tolmachev; Matti Anniko
Quantification of CD44v6 and EGFR expression in head and neck squamous cell carcinomas using a single-dose radioimmunoassay.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2007;28(5):253-63.
2007: Mikael Persson; Lars Gedda; Hans Lundqvist; Vladimir Tolmachev; Hans Nordgren; Per-Uno Malmstrom; Jörgen Carlsson
[177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts.
Cancer research 2007;67(1):326-31.
2006: Ylva Almqvist; Ann-Charlott Steffen; Vladimir Tolmachev; Chaitanya R Divgi; Anders Sundin
In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
Nuclear medicine and biology 2006;33(8):991-8.
2006: Johanna Höglund; Anna Orlova; Anders Sundin; Hans Lundqvist; Vladimir Tolmachev
Cellular processing in the SW1222 cell line of mAb A33 directly and indirectly radiohalogenated.
Oncology reports 2006;16(1):159-63.
2006: Ann-Charlott Steffen; Anna Orlova; Maria Wikman; Fredrik Y Nilsson; Stefan Ståhl; Gregory P Adams; Vladimir Tolmachev; Jörgen Carlsson
Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice.
European journal of nuclear medicine and molecular imaging 2006;33(6):631-8.
2006: Vladimir Tolmachev; Fredrik Y Nilsson; Charles Widström; Karl Andersson; Daniel Rosik; Lars Gedda; Anders Wennborg; Anna Orlova
111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(5):846-53.
2006: Anna Orlova; Mikaela Magnusson; Tove L J Eriksson; Martin Nilsson; Barbro Larsson; Ingmarie Höidén Guthenberg; Charles Widström; Jörgen Carlsson; Vladimir Tolmachev; Stefan Ståhl; Fredrik Y Nilsson
Tumor imaging using a picomolar affinity HER2 binding affibody molecule.
Cancer research 2006;66(8):4339-48.
2006: Anna Orlova; Alexander Bruskin; Igor Sivaev; Stefan Sjöberg; Hans Lundqvist; Vladimir Tolmachev
Radio-iodination of monoclonal antibody using potassium [125I]-(4-isothiocyanatobenzylammonio)-iodo-decahydro-closo-dodecaborate (iodo-DABI).
Anticancer research 2006;26(2A):1217-23.
2006: Anna Orlova; Fredrik Y Nilsson; Maria Wikman; Charles Widström; Stefan Ståhl; Jörgen Carlsson; Vladimir Tolmachev
Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(3):512-9.
2006: M I Persson; Lars Gedda; Holger J Jensen; Hans Lundqvist; Per-Uno Malmstrom; Vladimir Tolmachev
Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours.
Oncology reports 2006;15(3):673-80.
2006: Jörgen Carlsson; Zhi-Ping Ren; Kenneth Wester; Asa Liljegren Sundberg; Nils-Erik Heldin; Göran Hesselager; Mikael Persson; Lars Gedda; Vladimir Tolmachev; Hans Lundqvist; Erik Blomquist; Monica Nistér
Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression.
Journal of neuro-oncology 2006;77(1):33-45.
2005: Mikael Persson; Vladimir Tolmachev; Karl Andersson; Lars Gedda; Mattias Sandström; Jörgen Carlsson
[(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells.
European journal of nuclear medicine and molecular imaging 2005;32(12):1457-62.
2005: Eskender Mume; Anna Orlova; Barbro Larsson; Ann-Sofie Nilsson; Fredrik Y Nilsson; Stefan Sjöberg; Vladimir Tolmachev
Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody.
Bioconjugate chemistry 2005;16(6):1547-55.
2005: Irina Velikyan; Asa Liljegren Sundberg; Orjan Lindhe; A Urban Höglund; Olof Eriksson; Eva Werner; Jörgen Carlsson; Mats Bergström; Bengt Långström; Vladimir Tolmachev
Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(11):1881-8.
2005: Erika Bohl Kullberg; Bo Stenerlöw; Senait Ghirmai; Hans Lundqvist; Per-Uno Malmstrom; Anna Orlova; Vladimir Tolmachev; Lars Gedda
An aminoacridine derivative for radionuclide therapy: DNA binding properties studied in a novel cell-free in vitro assay.
International journal of oncology 2005;27(5):1355-60.
2005: Marika Nestor; Mikael Persson; Guus A M S van Dongen; Holger J Jensen; Hans Lundqvist; Matti Anniko; Vladimir Tolmachev
In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma.
European journal of nuclear medicine and molecular imaging 2005;32(11):1296-304.
2005: Ylva Almqvist; Anna Orlova; Anna Sjöström; Holger J Jensen; Hans Lundqvist; Anders Sundin; Vladimir Tolmachev
In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma.
Cancer biotherapy & radiopharmaceuticals 2005;20(5):514-23.
2005: Eskender Mume; Anna Orlova; Per-Uno Malmstrom; Hans Lundqvist; Stefan Sjöberg; Vladimir Tolmachev
Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET.
Nuclear medicine and biology 2005;32(6):613-22.
2005: Ann-Charlott Steffen; Maria Wikman; Vladimir Tolmachev; Gregory P Adams; Fredrik Y Nilsson; Stefan Ståhl; Jörgen Carlsson
In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics.
Cancer biotherapy & radiopharmaceuticals 2005;20(3):239-48.
2005: Mohammad Hossein Babaei; Ylva Almqvist; Anna Orlova; Mohammad Shafii; Kalevi Kairemo; Vladimir Tolmachev
[99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: preparation and pre-clinical evaluation.
Oncology reports 2005;13(6):1169-75.
2005: Senait Ghirmai; Eskender Mume; Vladimir Tolmachev; Stefan Sjöberg
Synthesis and radioiodination of some daunorubicin and doxorubicin derivatives.
Carbohydrate research 2005;340(1):15-24.
2004: Mattias Sandström; Vladimir Tolmachev; Kalevi Kairemo; Hans Lundqvist; Mark Lubberink
Performance of coincidence imaging with long-lived positron emitters as an alternative to dedicated PET and SPECT.
Physics in medicine and biology 2004;49(24):5419-32.
2004: Anna Orlova; Anna Sjöstrom; Ondrej Lebeda; Hans Lundqvist; Jörgen Carlsson; Vladimir Tolmachev
Targeting against epidermal growth factor receptors. Cellular processing of astatinated EGF after binding to cultured carcinoma cells.
Anticancer research 2004;24(6):4035-41.
2004: Junping Cheng; Mikael Persson; Vladimir Tolmachev; Igor Siavaev; Anna Orlova; Kalevi Kairemo; Matti Anniko
Targeting of a head and neck squamous cell carcinoma xenograft model using the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker.
Acta oto-laryngologica 2004;124(9):1078-85.
2004: Vladimir Tolmachev; Anna Orlova; Qichun Wei; Alexander Bruskin; Jörgen Carlsson; Lars Gedda
Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice.
Cancer biotherapy & radiopharmaceuticals 2004;19(4):491-501.
2004: Maria Wikman; A-C Steffen; Elin Gunneriusson; Vladimir Tolmachev; Gregory P Adams; J Carlsson; Stefan Ståhl
Selection and characterization of HER2/neu-binding affibody ligands.
Protein engineering, design & selection : PEDS 2004;17(5):455-62.
2004: Karl Johan Winberg; Mikael Persson; Per-Uno Malmstrom; Stefan Sjöberg; Vladimir Tolmachev
Radiobromination of anti-HER2/neu/ErbB-2 monoclonal antibody using the p-isothiocyanatobenzene derivative of the [76Br]undecahydro-bromo-7,8-dicarba-nido-undecaborate(1-) ion.
Nuclear medicine and biology 2004;31(4):425-33.
2004: Asa Liljegren Sundberg; Lars Gedda; Anna Orlova; Alexander Bruskin; Erik Blomquist; Jörgen Carlsson; Vladimir Tolmachev
[177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma.
Cancer biotherapy & radiopharmaceuticals 2004;19(2):195-204.
2004: Hans Lundqvist; Jörgen Carlsson; Lars Gedda; Vladimir Tolmachev; Ulrike Garske; Kalevi Kairemo
[Radionuclide therapy--a possible way toward an improved treatment of cancer. The obstacle is the shortage of commercially available radionuclides for clinical use].
Läkartidningen 2004;101(11):1000-2, 1005-6.
2004: Alexander Bruskin; Igor Sivaev; Mikael Persson; Hans Lundqvist; Jörgen Carlsson; Stefan Sjöberg; Vladimir Tolmachev
Radiobromination of monoclonal antibody using potassium [76Br] (4 isothiocyanatobenzyl-ammonio)-bromo-decahydro-closo-dodecaborate (Bromo-DABI).
Nuclear medicine and biology 2004;31(2):205-11.
2004: Vladimir Tolmachev; Jörgen Carlsson; Hans Lundqvist
A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy--availability of suitable radionuclides.
Acta oncologica (Stockholm, Sweden) 2004;43(3):264-75.
2003: Vladimir Tolmachev; Anna Orlova; Hans Lundqvist
Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides.
Current medicinal chemistry 2003;10(22):2447-60.
2003: Asa Liljegren Sundberg; Ylva Almqvist; Anna Orlova; Erik Blomquist; Holger J Jensen; Lars Gedda; Vladimir Tolmachev; Jörgen Carlsson
Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF.
European journal of nuclear medicine and molecular imaging 2003;30(10):1348-56.
2003: Asa Liljegren Sundberg; Anna Orlova; Alexander Bruskin; Lars Gedda; Jörgen Carlsson; Erik Blomquist; Hans Lundqvist; Vladimir Tolmachev
[(111)In]Bz-DTPA-hEGF: Preparation and in vitro characterization of a potential anti-glioblastoma targeting agent.
Cancer biotherapy & radiopharmaceuticals 2003;18(4):643-54.
2003: Marika Nestor; Mikael Persson; Junping Cheng; Vladimir Tolmachev; Guus A M S van Dongen; Matti Anniko; Kalevi Kairemo
Biodistribution of the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker. Comparison with other radioiodination methods.
Bioconjugate chemistry 2003;14(4):805-10.
2003: Asa Liljegren Sundberg; Ylva Almqvist; Vladimir Tolmachev; Jörgen Carlsson
Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition.
European journal of nuclear medicine and molecular imaging 2003;30(5):727-9.
2003: Soheir Beshara; Jens Sorensen; Mark Lubberink; Vladimir Tolmachev; Bengt Långström; Gunnar Antoni; Bo G Danielson; Hans Lundqvist
Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography.
British journal of haematology 2003;120(5):853-9.
2002: Mark Lubberink; Vladimir Tolmachev; Charles Widström; Alexander Bruskin; Hans Lundqvist; Jan-Erik Westlin
110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2002;43(10):1391-7.
2002: Anna Orlova; Johanna Höglund; Mark Lubberink; Ondrej Lebeda; Lars Gedda; Hans Lundqvist; Vladimir Tolmachev; Anders Sundin
Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implications for in vivo dosimetry.
Cancer biotherapy & radiopharmaceuticals 2002;17(4):385-96.
2002: Mark Lubberink; Hans Lundqvist; Vladimir Tolmachev
Production, PET performance and dosimetric considerations of 134Ce/134La, an Auger electron and positron-emitting generator for radionuclide therapy.
Physics in medicine and biology 2002;47(4):615-29.
2002: Hans Lundqvist; Vladimir Tolmachev
Targeting peptides and positron emission tomography.
Biopolymers 2002;66(6):381-92.
2002: Ulla Lindqvist; Vladimir Tolmachev; Kalevi Kairemo; Gunnar Aström; Eva Jonsson; Hans Lundqvist
Elimination of stabilised hyaluronan from the knee joint in healthy men.
Clinical pharmacokinetics 2002;41(8):603-13.
2000: U Mårs; Vladimir Tolmachev; Anders Sundin
Positron emission tomography of experimental melanoma with.
Nuclear medicine and biology 2000;27(8):845-9.
2000: Johanna Höglund; Vladimir Tolmachev; Anna Orlova; Hans Lundqvist; Anders Sundin
Optimized indirect (76)Br-bromination of antibodies using N-succinimidyl para-[76Br]bromobenzoate for radioimmuno PET.
Nuclear medicine and biology 2000;27(8):837-43.
2000: Anna Orlova; Alexander Bruskin; Anna Sjöström; Hans Lundqvist; Lars Gedda; Vladimir Tolmachev
Cellular processing of (125)I- and (111)in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells.
Nuclear medicine and biology 2000;27(8):827-35.
2000: Vladimir Tolmachev; P Bernhardt; Eva Forssell-Aronsson; Hans Lundqvist
114mIn, a candidate for radionuclide therapy: low-energy cyclotron production and labeling of DTPA-D-phe-octreotide.
Nuclear medicine and biology 2000;27(2):183-8.
1999: Mark Lubberink; Vladimir Tolmachev; Soheir Beshara; Hans Lundqvist
Quantification aspects of patient studies with 52Fe in positron emission tomography.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 1999;51(6):707-15.
1999: J Sundin; Vladimir Tolmachev; Jacek Koziorowski; Jörgen Carlsson; Hans Lundqvist; Sydney Welt; Steven M Larson; Anders Sundin
High yield direct 76Br-bromination of monoclonal antibodies using chloramine-T.
Nuclear medicine and biology 1999;26(8):923-9.
1999: Q Zhao; Vladimir Tolmachev; Jörgen Carlsson; Hans Lundqvist; J Sundin; Jan-Christer Janson; Anders Sundin
Effects of dextranation on the pharmacokinetics of short peptides. A PET study on mEGF.
Bioconjugate chemistry 1999;10(6):938-46.
1999: Vladimir Tolmachev; Jacek Koziorowski; Igor Sivaev; Hans Lundqvist; Jörgen Carlsson; Anna Orlova; Lars Gedda; Pär Olsson; Stefan Sjöberg; Anders Sundin
Closo-dodecaborate(2-) as a linker for iodination of macromolecules. Aspects on conjugation chemistry and biodistribution.
Bioconjugate chemistry 1999;10(3):338-45.
1999: P Garberg; Lars Engman; Vladimir Tolmachev; H Lundqvist; Robert Gerdes; Ian A Cotgreave
Binding of tellurium to hepatocellular selenoproteins during incubation with inorganic tellurite: consequences for the activity of selenium-dependent glutathione peroxidase.
The international journal of biochemistry & cell biology 1999;31(2):291-301.
1999: A Lövqvist; Hans Lundqvist; Mark Lubberink; Vladimir Tolmachev; Jörgen Carlsson; Anders Sundin
Kinetics of 76Br-labeled anti-CEA antibodies in pigs; aspects of dosimetry and PET imaging properties.
Medical physics 1999;26(2):249-58.
1999: Soheir Beshara; Hans Lundqvist; J Sundin; Mark Lubberink; Vladimir Tolmachev; S Valind; Gunnar Antoni; Bengt Långström; Bo G Danielson
Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography.
British journal of haematology 1999;104(2):296-302.
1999: Soheir Beshara; Hans Lundqvist; J Sundin; Mark Lubberink; Vladimir Tolmachev; S Valind; Gunnar Antoni; Bengt Långström; Bo G Danielson
Kinetic analysis of 52Fe-labelled iron(III) hydroxide-sucrose complex following bolus administration using positron emission tomography.
British journal of haematology 1999;104(2):288-95.
1999: Mark Lubberink; Hans Lundqvist; Jan-Erik Westlin; Vladimir Tolmachev; H Schneider; A Lövqvist; Anders Sundin; Jörgen Carlsson
Positron emission tomography and radioimmunotargeting--aspects of quantification and dosimetry.
Acta oncologica (Stockholm, Sweden) 1999;38(3):343-9.
1999: Hans Lundqvist; Mark Lubberink; Vladimir Tolmachev; A Lövqvist; Anders Sundin; Soheir Beshara; Alexander Bruskin; Jörgen Carlsson; Jan-Erik Westlin
Positron emission tomography and radioimmunotargeting--general aspects.
Acta oncologica (Stockholm, Sweden) 1999;38(3):335-41.
1999: Jörgen Carlsson; Erik Blomquist; Lars Gedda; A Liljegren; Per-Uno Malmstrom; Anna Sjöström; Anders Sundin; Jan-Erik Westlin; Q Zhao; Vladimir Tolmachev; Hans Lundqvist
Conjugate chemistry and cellular processing of EGF-dextran.
Acta oncologica (Stockholm, Sweden) 1999;38(3):313-21.
1998: Mats Bergström; L Lu; Karl-Johan Fasth; F Wu; E Bergström-Pettermann; Vladimir Tolmachev; E Hedberg; A Cheng; Bengt Långström
In vitro and animal validation of bromine-76-bromodeoxyuridine as a proliferation marker.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1998;39(7):1273-9.
1998: Q Zhao; Erik Blomquist; H Bolander; Lars Gedda; P Hartvig; Jan-Christer Janson; Hans Lundqvist; Håkan Mellstedt; S Nilsson; M Nistèr; Anders Sundin; Vladimir Tolmachev; Jan-Erik Westlin; J Carlsson
Conjugate chemistry, iodination and cellular binding of mEGF-dextran-tyrosine: preclinical tests in preparation for clinical trials.
International journal of molecular medicine 1998;1(4):693-702.
1998: Vladimir Tolmachev; Hans Lundqvist; L Einarsson
Production of 61Cu from a natural nickel target.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 1998;49(1-2):79-81.